✦ LIBER ✦

Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients

✍ Scribed by P. P. De Deyn; V. Van de Velde; W. Verslegers; J. Saerens; B. A. Pickut; B. Clincke; R. Woestenborghs; A. Van Peer

Publisher: Springer
Year: 1992
Tongue: English
Weight: 278 KB
Volume: 43
Category: Article
ISSN: 0031-6970
DOI: 10.1007/bf02284969

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of IV and oral acetyl-L

Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type

✍ L. Parnetti; A. Gaiti; P. Mecocci; D. Cadini; U. Senin 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 419 KB

Pharmacokinetics of IV and oral acetyl-L

Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type

✍ L. Parnetti; A. Gaiti; P. Mecocci; D. Cadini; U. Senin 📂 Article 📅 1993 🏛 Springer 🌐 English ⚖ 29 KB

Abnormal pattern electroretinograms in p

Abnormal pattern electroretinograms in patients with senile dementia of the alzheimer type

✍ Dr Gary L Trick; Michael C Barris; Michelle Bickler-Bluth 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 668 KB

Olfactory identification is impaired in

Olfactory identification is impaired in clinic-based patients with vascular dementia and senile dementia of Alzheimer type

✍ Alison J. Gray; Vince Staples; Karen Murren; Avtar Dhariwal; Peter Bentham 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB 👁 1 views

## Abstract ## Aims It is now well established that there are abnormalities in the sense of smell in patients suffering from Alzheimer's disease (AD). They have both raised olfactory thresholds and impaired odour identification. The situation in vascular dementia is unclear. We used the University

Alaproclate: A pharmacokinetic and bioch

Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of Alzheimer type

✍ I. Bergman; G. Brane; C. G. Gottfries; K. -G. Jostell; I. Karlsson; L. Svennerho 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 450 KB

Alaproclate, a specific inhibitor of neuronal serotonin re-uptake, was given to 12 patients with dementia of Alzheimer type. The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated. Plasma protein binding for alaproclate was 82 +/- 1%. Two weeks of

Single intravenous dose and steady-state

Single intravenous dose and steady-state oral dose pharmacokinetics of nicardipine in healthy subjects

✍ John G. Wagner; Teck L. Ling; Edward J. Mroszczak; Donna Freedman; Ann Wu; Bee H 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 English ⚖ 617 KB

Nicardipine HCI oral doses (10-40 mg) were administered sequentially to six healthy subjects. For each regimen the capsule dose was administered every 8 hours (q 8 h) for 3 days and the plasma profiles of nicardipine and its pyridine analogue (M5) were determined following the last dose on day 4. St